These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 38644245

  • 1. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
    Yang XQ, Rao Z, Wei HK, Xue ZC, Liu HY, Duan QF, Sun XW, Wang W.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr 25; 27(4):395-402. PubMed ID: 38644245
    [Abstract] [Full Text] [Related]

  • 2. [Analysis of the efficacy and safety of preoperative programmed death protein-1 inhibitor combined with chemotherapy in immunotherapy-sensitive patients with locally advanced gastric cancer or adenocarcinoma of the esophagogastric junction].
    Li YJ, Yuan P, Zhai JN, Yao YF, Tan LX, Li ZW, Zhang XY, Wu AW.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Jul 25; 27(7):684-693. PubMed ID: 39004983
    [Abstract] [Full Text] [Related]

  • 3. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
    Lv JB, Yin YP, Zhang P, Cai M, Chen JH, Li W, Li G, Wang Z, Wang GB, Tao KX.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan 25; 26(1):84-92. PubMed ID: 36650004
    [Abstract] [Full Text] [Related]

  • 4. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y, Wang Q, Wang J, Qiao XY, Zhang J, Lin YC, Li Y, Fan LQ, Yang PG, Zhao Q.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb 25; 24(2):128-137. PubMed ID: 33508918
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparative efficacy of treatments for previously treated patients with advanced esophageal and esophagogastric junction cancer: A network meta-analysis.
    Lin S, Liu T, Chen J, Li G, Dang J.
    PLoS One; 2021 Feb 25; 16(6):e0252751. PubMed ID: 34086780
    [Abstract] [Full Text] [Related]

  • 9. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X, Liang H, Li Z, Xue Y, Wang Y, Zhou Z, Yu J, Bu Z, Chen L, Du Y, Wang X, Wu A, Li G, Su X, Xiao G, Cui M, Wu D, Chen L, Wu X, Zhou Y, Zhang L, Dang C, He Y, Zhang Z, Sun Y, Li Y, Chen H, Bai Y, Qi C, Yu P, Zhu G, Suo J, Jia B, Li L, Huang C, Li F, Ye Y, Xu H, Wang X, Yuan Y, E JY, Ying X, Yao C, Shen L, Ji J, RESOLVE study group.
    Lancet Oncol; 2021 Aug 25; 22(8):1081-1092. PubMed ID: 34252374
    [Abstract] [Full Text] [Related]

  • 10. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
    Cho JH, Lim JY, Cho JY.
    PLoS One; 2017 Aug 25; 12(10):e0186362. PubMed ID: 29040299
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage.
    Shin K, Park SJ, Lee J, Park CH, Song KY, Lee HH, Seo HS, Jung YJ, Park JM, Lee SH, Roh SY, Kim IH.
    BMC Cancer; 2019 Dec 18; 19(1):1232. PubMed ID: 31852475
    [Abstract] [Full Text] [Related]

  • 12. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW, Zheng ZC, Zhao Q, Zhai G, Liang H, Wu X, Zhu ZG, Wang HJ, He QS, He XL, Du YA, Chen LC, Hua YW, Huang CM, Xue YW, Zhou Y, Zhou YB, Wu D, Fang XD, Dai YG, Zhang HW, Cao JQ, Li LP, Chai J, Tao KX, Li GL, Jie ZG, Ge J, Xu ZF, Zhang WB, Li QY, Zhao P, Ma ZQ, Yan ZL, Zheng GL, Yan Y, Tang XL, Zhou X.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May 25; 24(5):403-412. PubMed ID: 34000769
    [Abstract] [Full Text] [Related]

  • 13. [Survival comparison of Siewert II adenocarcinoma of esophagogastric junction between transthoracic and transabdominal approaches:a joint data analysis of thoracic and gastrointestinal surgery].
    Yang S, Yuan Y, Hu H, Li R, Liu K, Zhang W, Yang K, Yang Y, Bai D, Chen X, Zhou Z, Chen L.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Feb 25; 22(2):132-142. PubMed ID: 30799535
    [Abstract] [Full Text] [Related]

  • 14. Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT.
    Liu X, Jin J, Cai H, Huang H, Zhao G, Zhou Y, Wu J, Du C, Long Z, Fang Y, Ma M, Li G, Zhou M, Yin J, Zhu X, Zhu J, Sheng W, Huang D, Zhu H, Zhang Z, Lu Q, Xie L, Zhang Z, Wang Y.
    BMC Cancer; 2019 Jun 20; 19(1):606. PubMed ID: 31221115
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
    Ryoo BY, Kang YK, Im YH, Kim YJ, Kim BS, Kim TY, Jung SH, Park JH, Baek HJ, Kim YC, Shim YM, Kim CM, Zo JI.
    Am J Clin Oncol; 1999 Jun 20; 22(3):253-7. PubMed ID: 10362331
    [Abstract] [Full Text] [Related]

  • 16. Clinical outcomes of radical gastrectomy following trastuzumab-based chemotherapy for stage IV HER2-positive gastric or gastroesophageal junction cancer.
    Takahashi R, Nunobe S, Osumi H, Takahari D, Yamamoto N, Ida S, Kumagai K, Ohashi M, Sano T, Hiki N.
    Surg Today; 2020 Oct 20; 50(10):1240-1248. PubMed ID: 32451714
    [Abstract] [Full Text] [Related]

  • 17. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
    Sun YT, Lu SX, Lai MY, Yang X, Guan WL, Yang LQ, Li YH, Wang FH, Yang DJ, Qiu MZ.
    Cancer Immunol Immunother; 2024 Jun 04; 73(8):144. PubMed ID: 38832979
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10.
    Wainberg ZA, Fuchs CS, Tabernero J, Shitara K, Muro K, Van Cutsem E, Bang YJ, Chung HC, Yamaguchi K, Varga E, Chen JS, Hochhauser D, Thuss-Patience P, Al-Batran SE, Garrido M, Kher U, Shih CS, Shah S, Bhagia P, Chao J.
    Clin Cancer Res; 2021 Apr 01; 27(7):1923-1931. PubMed ID: 33446564
    [Abstract] [Full Text] [Related]

  • 19. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
    He MM, Zhang DS, Wang F, Wang ZQ, Luo HY, Ren C, Jin Y, Chen DL, Xu RH.
    World J Gastroenterol; 2014 Jan 07; 20(1):264-73. PubMed ID: 24415881
    [Abstract] [Full Text] [Related]

  • 20. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.
    Li J, Bai Y, Chen Z, Ying J, Guo Y, Fang W, Zhang F, Xiong J, Zhang T, Meng Z, Zhang J, Ren Z, Hao C, Chen Y, Lin X, Pan H, Zhou F, Li X, Yu F, Zhang J, Zhang Z, Qin S.
    Cancer Immunol Immunother; 2024 Sep 05; 73(11):219. PubMed ID: 39235596
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.